首页 > 最新文献

Journal of Translational Autoimmunity最新文献

英文 中文
Across ancestries, HLA-B∗08:01∼DRB1∗03:01 (DR3) and HLA-DQA∗01:02 (DR2) increase the risk to develop juvenile-onset systemic lupus erythematosus through low complement C4 levels
IF 4.7 Q2 IMMUNOLOGY Pub Date : 2025-01-07 DOI: 10.1016/j.jtauto.2025.100268
Yves Renaudineau , Amandine Charras , Valentina Natoli , Nicolas Congy-Jolivet , Sam Haldenby , Xuan Liu , Yongxiang Fang , Eve MD. Smith , Michael W. Beresford , Christian M. Hedrich

Objective

Systemic lupus erythematosus (SLE) is a systemic autoimmune/inflammatory disease with a strong genetic component. Genetic burden is higher in children when compared to patients with adult-onset SLE, contributing to earlier disease expression and more severe phenotypes. The human leukocyte antigen (HLA) cluster on chromosome 6p21.3 is among the most variable genomic regions, representing a major risk-factor for SLE in adults. Its impact on juvenile-onset (j)SLE remains largely unstudied.

Methods

High-resolution sequencing of HLA class I (A, B, C), class II (DRB1, DQA1, DQB1) and class III (complement C2) was undertaken in the multi-ancestral UK JSLE Cohort including participants of Caucasian (n = 151, 48.8 %), Asian (n = 108, 35.0 %) and African/Caribbean (n = 50, 16.2 %) descent. Considering ancestral variation, clinical associations were tested at the level of alleles (2-field resolution), associated HLA protein sequences (antigen binding domains, 4-field resolution), and extended haplotypes (DRh).

Results

Although important ancestral recombination was reported for HLA-DR2 and -DR3 haplotypes, risk associated with jSLE was conserved at related alleles (DR2h: DRB1∗15:01, DQA∗01:02, DQB1∗06:02; DR3h: C∗07:02 [Asian], B∗08:01, C2 rs9332730 [Asian], DRB1∗03:01). HLA-DR7 haplotypes (DRB1∗07:01, OR = 0.44, 95 % CI:0.27–0.72, p = 0.0004; DQA1∗02:01, OR = 0.34, 95 % CI:0.21–0.56, p = 1.8 × 10−6) protect Asians from jSLE development. Among 23 clinical variables recorded, the main association was found between low levels of complement C4 in Caucasian carriers of HLA-DR3h. This was not the case in Asians due to recombination with HLA-C∗07:02 and integration of the C2 rs9332730 minor allele. Low C4 serum levels associated with HLA-DQA1∗01:02 (DR2h) in Caucasians after excluding HLA-DR3h carriers from the analysis. An association between low white blood cell counts and HLA-A∗03:01P was observed across ancestries.

Conclusion

Genetic variation in the HLA cluster associates with organ domain involvement (hematological) and complement levels in jSLE. Lupus-associated HLA haplotypes vary between ancestral groups, underscoring the importance of multi-ancestral approaches to genetic studies in SLE and other autoimmune/inflammatory diseases.
{"title":"Across ancestries, HLA-B∗08:01∼DRB1∗03:01 (DR3) and HLA-DQA∗01:02 (DR2) increase the risk to develop juvenile-onset systemic lupus erythematosus through low complement C4 levels","authors":"Yves Renaudineau ,&nbsp;Amandine Charras ,&nbsp;Valentina Natoli ,&nbsp;Nicolas Congy-Jolivet ,&nbsp;Sam Haldenby ,&nbsp;Xuan Liu ,&nbsp;Yongxiang Fang ,&nbsp;Eve MD. Smith ,&nbsp;Michael W. Beresford ,&nbsp;Christian M. Hedrich","doi":"10.1016/j.jtauto.2025.100268","DOIUrl":"10.1016/j.jtauto.2025.100268","url":null,"abstract":"<div><h3>Objective</h3><div>Systemic lupus erythematosus (SLE) is a systemic autoimmune/inflammatory disease with a strong genetic component. Genetic burden is higher in children when compared to patients with adult-onset SLE, contributing to earlier disease expression and more severe phenotypes. The human leukocyte antigen (HLA) cluster on chromosome 6p21.3 is among the most variable genomic regions, representing a major risk-factor for SLE in adults. Its impact on juvenile-onset (j)SLE remains largely unstudied.</div></div><div><h3>Methods</h3><div>High-resolution sequencing of HLA class I (A, B, C), class II (DRB1, DQA1, DQB1) and class III (complement <em>C2</em>) was undertaken in the multi-ancestral UK JSLE Cohort including participants of Caucasian (n = 151, 48.8 %), Asian (n = 108, 35.0 %) and African/Caribbean (n = 50, 16.2 %) descent. Considering ancestral variation, clinical associations were tested at the level of alleles (2-field resolution), associated HLA protein sequences (antigen binding domains, 4-field resolution), and extended haplotypes (DRh).</div></div><div><h3>Results</h3><div>Although important ancestral recombination was reported for HLA-DR2 and -DR3 haplotypes, risk associated with jSLE was conserved at related alleles (DR2h: DRB1∗15:01, DQA∗01:02, DQB1∗06:02; DR3h: C∗07:02 [Asian], B∗08:01, <em>C2</em> rs9332730 [Asian], DRB1∗03:01). HLA-DR7 haplotypes (DRB1∗07:01, OR = 0.44, 95 % CI:0.27–0.72, p = 0.0004; DQA1∗02:01, OR = 0.34, 95 % CI:0.21–0.56, p = 1.8 × 10<sup>−6</sup>) protect Asians from jSLE development. Among 23 clinical variables recorded, the main association was found between low levels of complement C4 in Caucasian carriers of HLA-DR3h. This was not the case in Asians due to recombination with HLA-C∗07:02 and integration of the <em>C2</em> rs9332730 minor allele. Low C4 serum levels associated with HLA-DQA1∗01:02 (DR2h) in Caucasians after excluding HLA-DR3h carriers from the analysis. An association between low white blood cell counts and HLA-A∗03:01P was observed across ancestries.</div></div><div><h3>Conclusion</h3><div>Genetic variation in the <em>HLA</em> cluster associates with organ domain involvement (hematological) and complement levels in jSLE. Lupus-associated <em>HLA</em> haplotypes vary between ancestral groups, underscoring the importance of multi-ancestral approaches to genetic studies in SLE and other autoimmune/inflammatory diseases.</div></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"10 ","pages":"Article 100268"},"PeriodicalIF":4.7,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11786776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular mimicry in the pathogenesis of autoimmune rheumatic diseases
IF 4.7 Q2 IMMUNOLOGY Pub Date : 2025-01-07 DOI: 10.1016/j.jtauto.2025.100269
Michaela Fehringer, Thomas Vogl
Autoimmune rheumatic diseases (ARDs) are a heterogeneous group of conditions characterized by excessive and misdirected immune responses against the body's own musculoskeletal tissues. Their exact aetiology remains unclear, with genetic, demographic, behavioural and environmental factors implicated in disease onset. One prominent hypothesis for the initial breach of immune tolerance (leading to autoimmunity) is molecular mimicry, which describes structural or sequence similarities between human and microbial proteins (mimotopes). This similarity can lead to cross-reactive antibodies and T-cell receptors, resulting in an immune response against autoantigens. Both commensal microbes in the human microbiome and pathogens can trigger molecular mimicry, thereby potentially contributing to the onset of ARDs.
In this review, we focus on the role of molecular mimicry in the onset of rheumatoid arthritis and systemic lupus erythematosus. Moreover, implications of molecular mimicry are also briefly discussed for ankylosing spondylitis, systemic sclerosis and myositis.
{"title":"Molecular mimicry in the pathogenesis of autoimmune rheumatic diseases","authors":"Michaela Fehringer,&nbsp;Thomas Vogl","doi":"10.1016/j.jtauto.2025.100269","DOIUrl":"10.1016/j.jtauto.2025.100269","url":null,"abstract":"<div><div>Autoimmune rheumatic diseases (ARDs) are a heterogeneous group of conditions characterized by excessive and misdirected immune responses against the body's own musculoskeletal tissues. Their exact aetiology remains unclear, with genetic, demographic, behavioural and environmental factors implicated in disease onset. One prominent hypothesis for the initial breach of immune tolerance (leading to autoimmunity) is molecular mimicry, which describes structural or sequence similarities between human and microbial proteins (mimotopes). This similarity can lead to cross-reactive antibodies and T-cell receptors, resulting in an immune response against autoantigens. Both commensal microbes in the human microbiome and pathogens can trigger molecular mimicry, thereby potentially contributing to the onset of ARDs.</div><div>In this review, we focus on the role of molecular mimicry in the onset of rheumatoid arthritis and systemic lupus erythematosus. Moreover, implications of molecular mimicry are also briefly discussed for ankylosing spondylitis, systemic sclerosis and myositis.</div></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"10 ","pages":"Article 100269"},"PeriodicalIF":4.7,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143060841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Large soluble CD18 complexes with exclusive ICAM-1-binding properties are shed during immune cell migration in inflammation
IF 4.7 Q2 IMMUNOLOGY Pub Date : 2025-01-05 DOI: 10.1016/j.jtauto.2025.100266
Alexey Ferapontov , Anders Mellemkjær , Helen M. McGettrick , Thomas Vorup-Jensen , Tue W. Kragstrup , Kristian Juul-Madsen
The family of heterodimeric CD11/CD18 integrins facilitate leukocyte adhesion and migration in a wide range of normal physiologic responses, as well as in the pathology of inflammatory diseases. Soluble CD18 (sCD18) is found mainly in complexes with hydrodynamic radii of 5 and 7.2 nm, suggesting a compositional difference. Earlier work reported that the complexes include at least part of the CD11a or CD11b chains containing the intercellular adhesion molecule (ICAM)-1 binding domain, and that sCD18 is capable of quantitatively competing with the cell membrane-bound form for ICAM-1 binding. However, it is not clear if the size differences between the sCD18 complexes reflect any functional variance regarding shedding from the cell membrane or binding to ICAM-1. Here, we show evidence that sCD18 found in serum regulates release of the proinflammatory cytokine monocyte chemoattractant protein-1 (MCP-1/CCL2) from fibroblast-like synovial cells. Further, only large sCD18 complexes are capable of binding to ICAM-1. Migrating neutrophils shed large, but not small, sCD18 complexes. Together, these observations explain results measured from patients with rheumatoid arthritis (RA), where large sCD18 complexes dominated in local inflammatory processes involving neutrophil influx into zones of inflammation. Our data points to a previously unappreciated aspect of sCD18 integrin biology as regulators of inflammation in the context of migrating leukocyte. Surprisingly, this regulation is tied to sCD18 complex size, opening new opportunities for therapeutic intervention in serious inflammatory diseases such as arthritis.
{"title":"Large soluble CD18 complexes with exclusive ICAM-1-binding properties are shed during immune cell migration in inflammation","authors":"Alexey Ferapontov ,&nbsp;Anders Mellemkjær ,&nbsp;Helen M. McGettrick ,&nbsp;Thomas Vorup-Jensen ,&nbsp;Tue W. Kragstrup ,&nbsp;Kristian Juul-Madsen","doi":"10.1016/j.jtauto.2025.100266","DOIUrl":"10.1016/j.jtauto.2025.100266","url":null,"abstract":"<div><div>The family of heterodimeric CD11/CD18 integrins facilitate leukocyte adhesion and migration in a wide range of normal physiologic responses, as well as in the pathology of inflammatory diseases. Soluble CD18 (sCD18) is found mainly in complexes with hydrodynamic radii of 5 and 7.2 nm, suggesting a compositional difference. Earlier work reported that the complexes include at least part of the CD11a or CD11b chains containing the intercellular adhesion molecule (ICAM)-1 binding domain, and that sCD18 is capable of quantitatively competing with the cell membrane-bound form for ICAM-1 binding. However, it is not clear if the size differences between the sCD18 complexes reflect any functional variance regarding shedding from the cell membrane or binding to ICAM-1. Here, we show evidence that sCD18 found in serum regulates release of the proinflammatory cytokine monocyte chemoattractant protein-1 (MCP-1/CCL2) from fibroblast-like synovial cells. Further, only large sCD18 complexes are capable of binding to ICAM-1. Migrating neutrophils shed large, but not small, sCD18 complexes. Together, these observations explain results measured from patients with rheumatoid arthritis (RA), where large sCD18 complexes dominated in local inflammatory processes involving neutrophil influx into zones of inflammation. Our data points to a previously unappreciated aspect of sCD18 integrin biology as regulators of inflammation in the context of migrating leukocyte. Surprisingly, this regulation is tied to sCD18 complex size, opening new opportunities for therapeutic intervention in serious inflammatory diseases such as arthritis.</div></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"10 ","pages":"Article 100266"},"PeriodicalIF":4.7,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iron metabolism in rheumatic diseases
IF 4.7 Q2 IMMUNOLOGY Pub Date : 2025-01-04 DOI: 10.1016/j.jtauto.2025.100267
Aliakbar Givian , Amin Azizan , Ahmadreza Jamshidi , Mahdi Mahmoudi , Elham Farhadi
Iron is a crucial element for living organism in terms of oxygen transport, hematopoiesis, enzymatic activity, mitochondrial respiratory chain function and also immune system function. The human being has evolved a mechanism to regulate body iron. In some rheumatic diseases such as rheumatoid arthritis (RA), systemic lupus erythematous (SLE), systemic sclerosis (SSc), ankylosing spondylitis (AS), and gout, this balanced iron regulation is impaired. Altered iron homeostasis can contribute to disease progression through ROS production, fibrosis, inflammation, abnormal bone homeostasis, NETosis and cell senescence. In this review, we have focused on the iron metabolism in rheumatic disease and its role in disease progression.
{"title":"Iron metabolism in rheumatic diseases","authors":"Aliakbar Givian ,&nbsp;Amin Azizan ,&nbsp;Ahmadreza Jamshidi ,&nbsp;Mahdi Mahmoudi ,&nbsp;Elham Farhadi","doi":"10.1016/j.jtauto.2025.100267","DOIUrl":"10.1016/j.jtauto.2025.100267","url":null,"abstract":"<div><div>Iron is a crucial element for living organism in terms of oxygen transport, hematopoiesis, enzymatic activity, mitochondrial respiratory chain function and also immune system function. The human being has evolved a mechanism to regulate body iron. In some rheumatic diseases such as rheumatoid arthritis (RA), systemic lupus erythematous (SLE), systemic sclerosis (SSc), ankylosing spondylitis (AS), and gout, this balanced iron regulation is impaired. Altered iron homeostasis can contribute to disease progression through ROS production, fibrosis, inflammation, abnormal bone homeostasis, NETosis and cell senescence. In this review, we have focused on the iron metabolism in rheumatic disease and its role in disease progression.</div></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"10 ","pages":"Article 100267"},"PeriodicalIF":4.7,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11763848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of UV-induced cutaneous matrix metalloproteinases and mi-RNAs in the pathogenesis of lupus erythematosus 紫外线诱导的皮肤基质金属蛋白酶和mi- rna在红斑狼疮发病机制中的作用。
IF 4.7 Q2 IMMUNOLOGY Pub Date : 2024-12-28 DOI: 10.1016/j.jtauto.2024.100265
I. Ivanova, T. Svilenska, T. Maisch, S. Karrer, D. Niebel, M. Berneburg, B. Kurz
Cutaneous (CLE) and systemic lupus erythematosus (SLE) are autoimmune diseases with a multifactorial pathogenesis. Ultraviolet radiation (UVR) is the most important trigger of CLE; however, the degree of photosensitivity varies between the clinical subtypes. The expression of matrix metalloproteinases (MMPs)—important enzymes involved in skin turnover and homeostasis—is modulated by UVR.
To investigate the causality of the clinically observed effects of UVR, sun-exposed lesional skin samples from patients with different subtypes of lupus erythematosus (LE) were examined by immunohistochemistry for the expression of MMP1 and MMP28 and compared with biopsies from polymorphous light eruption (PLE) and healthy skin (HS). The expression of micro-RNAs (miR-31 and miR-150)—regulators of MMP expression and cellular metabolism—in the samples was determined by in-situ hybridization and correlated with the expression of the glucose transporter 1 (GLUT1) receptor to examine potential metabolic regulation. To assess potential UVR regulation of MMP28, we performed in vitro experiments in healthy keratinocytes and fibroblasts.
MMP28 expression was differentially affected by UVA1 and UVB irradiation in keratinocytes and fibroblasts. Compared with all other LE subtypes, as well as PLE and HS samples, MMP28 expression in Chilblain LE skin showed a distinct vertical distribution, reaching as far as the upper layers of the dermis. This vertical expression pattern coincided with decreased GLUT1 levels and with increased expression of miR-31 and miR-150 in the epidermis of patients with Chilblain LE. These data provide evidence for a potential metabolic dysregulation that may play a role in the etiology of LE. Furthermore, our results suggest MMP28 as a novel complementary marker in Chilblain LE diagnosis.
皮肤性红斑狼疮(CLE)和系统性红斑狼疮(SLE)是多因素发病的自身免疫性疾病。紫外线辐射(UVR)是CLE最重要的诱发因素;然而,不同临床亚型的光敏程度不同。基质金属蛋白酶(matrix metalloproteinases, MMPs)是参与皮肤更新和体内平衡的重要酶,其表达可被紫外线照射调节。为了研究UVR临床效应的因果关系,我们采用免疫组织化学方法检测了不同亚型红斑狼疮(LE)患者晒伤皮肤样本中MMP1和MMP28的表达,并与多形光疹(PLE)和健康皮肤(HS)的活检组织进行了比较。通过原位杂交检测样品中调控MMP表达和细胞代谢的微rna (miR-31和miR-150)的表达,并与葡萄糖转运蛋白1 (GLUT1)受体的表达相关,以检测潜在的代谢调节。为了评估UVR对MMP28的潜在调节作用,我们在健康的角质形成细胞和成纤维细胞中进行了体外实验。UVA1和UVB辐照对角质形成细胞和成纤维细胞中MMP28的表达有不同的影响。与其他LE亚型以及LE和HS样本相比,冻疮LE皮肤中MMP28的表达呈明显的垂直分布,最远可达真皮层上层。这种垂直表达模式与冻疮LE患者表皮中GLUT1水平下降以及miR-31和miR-150表达增加相吻合。这些数据为可能在LE病因中发挥作用的潜在代谢失调提供了证据。此外,我们的研究结果表明MMP28是冻疮LE诊断的一种新的补充标记。
{"title":"The role of UV-induced cutaneous matrix metalloproteinases and mi-RNAs in the pathogenesis of lupus erythematosus","authors":"I. Ivanova,&nbsp;T. Svilenska,&nbsp;T. Maisch,&nbsp;S. Karrer,&nbsp;D. Niebel,&nbsp;M. Berneburg,&nbsp;B. Kurz","doi":"10.1016/j.jtauto.2024.100265","DOIUrl":"10.1016/j.jtauto.2024.100265","url":null,"abstract":"<div><div>Cutaneous (CLE) and systemic lupus erythematosus (SLE) are autoimmune diseases with a multifactorial pathogenesis. Ultraviolet radiation (UVR) is the most important trigger of CLE; however, the degree of photosensitivity varies between the clinical subtypes. The expression of matrix metalloproteinases (MMPs)—important enzymes involved in skin turnover and homeostasis—is modulated by UVR.</div><div>To investigate the causality of the clinically observed effects of UVR, sun-exposed lesional skin samples from patients with different subtypes of lupus erythematosus (LE) were examined by immunohistochemistry for the expression of MMP1 and MMP28 and compared with biopsies from polymorphous light eruption (PLE) and healthy skin (HS). The expression of micro-RNAs (miR-31 and miR-150)—regulators of MMP expression and cellular metabolism—in the samples was determined by in-situ hybridization and correlated with the expression of the glucose transporter 1 (GLUT1) receptor to examine potential metabolic regulation. To assess potential UVR regulation of MMP28, we performed <em>in vitro</em> experiments in healthy keratinocytes and fibroblasts.</div><div>MMP28 expression was differentially affected by UVA1 and UVB irradiation in keratinocytes and fibroblasts. Compared with all other LE subtypes, as well as PLE and HS samples, MMP28 expression in Chilblain LE skin showed a distinct vertical distribution, reaching as far as the upper layers of the dermis. This vertical expression pattern coincided with decreased GLUT1 levels and with increased expression of miR-31 and miR-150 in the epidermis of patients with Chilblain LE. These data provide evidence for a potential metabolic dysregulation that may play a role in the etiology of LE. Furthermore, our results suggest MMP28 as a novel complementary marker in Chilblain LE diagnosis.</div></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"10 ","pages":"Article 100265"},"PeriodicalIF":4.7,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11743922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cellular therapies in rheumatic and musculoskeletal diseases
IF 4.7 Q2 IMMUNOLOGY Pub Date : 2024-12-16 DOI: 10.1016/j.jtauto.2024.100264
Pedro Franco-Fuquen , Juana Figueroa-Aguirre , David A. Martínez , Eider F. Moreno-Cortes , Juan E. Garcia-Robledo , Fabio Vargas-Cely , Daniela A. Castro-Martínez , Mustafa Almaini , Januario E. Castro
A substantial proportion of patients diagnosed with rheumatologic and musculoskeletal diseases (RMDs) exhibit resistance to conventional therapies or experience recurrent symptoms. These diseases, which include autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, are marked by the presence of autoreactive B cells that play a critical role in their pathogenesis. The persistence of these autoreactive B cells within lymphatic organs and inflamed tissues impairs the effectiveness of B-cell-depleting monoclonal antibodies like rituximab.
A promising therapeutic approach involves using T cells genetically engineered to express chimeric antigen receptors (CARs) that target specific antigens. This strategy has demonstrated efficacy in treating B-cell malignancies by achieving long-term depletion of malignant and normal B cells. Preliminary data from patients with RMDs, particularly those with lupus erythematosus and dermatomyositis, suggest that CAR T-cells targeting CD19 can induce rapid and sustained depletion of circulating B cells, leading to complete clinical and serological responses in cases that were previously unresponsive to conventional therapies.
This review will provide an overview of the current state of preclinical and clinical studies on the use of CAR T-cells and other cellular therapies for RMDs. Additionally, it will explore potential future applications of these innovative treatment modalities for managing patients with refractory and recurrent manifestations of these diseases.
{"title":"Cellular therapies in rheumatic and musculoskeletal diseases","authors":"Pedro Franco-Fuquen ,&nbsp;Juana Figueroa-Aguirre ,&nbsp;David A. Martínez ,&nbsp;Eider F. Moreno-Cortes ,&nbsp;Juan E. Garcia-Robledo ,&nbsp;Fabio Vargas-Cely ,&nbsp;Daniela A. Castro-Martínez ,&nbsp;Mustafa Almaini ,&nbsp;Januario E. Castro","doi":"10.1016/j.jtauto.2024.100264","DOIUrl":"10.1016/j.jtauto.2024.100264","url":null,"abstract":"<div><div>A substantial proportion of patients diagnosed with rheumatologic and musculoskeletal diseases (RMDs) exhibit resistance to conventional therapies or experience recurrent symptoms. These diseases, which include autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, are marked by the presence of autoreactive B cells that play a critical role in their pathogenesis. The persistence of these autoreactive B cells within lymphatic organs and inflamed tissues impairs the effectiveness of B-cell-depleting monoclonal antibodies like rituximab.</div><div>A promising therapeutic approach involves using T cells genetically engineered to express chimeric antigen receptors (CARs) that target specific antigens. This strategy has demonstrated efficacy in treating B-cell malignancies by achieving long-term depletion of malignant and normal B cells. Preliminary data from patients with RMDs, particularly those with lupus erythematosus and dermatomyositis, suggest that CAR T-cells targeting CD19 can induce rapid and sustained depletion of circulating B cells, leading to complete clinical and serological responses in cases that were previously unresponsive to conventional therapies.</div><div>This review will provide an overview of the current state of preclinical and clinical studies on the use of CAR T-cells and other cellular therapies for RMDs. Additionally, it will explore potential future applications of these innovative treatment modalities for managing patients with refractory and recurrent manifestations of these diseases.</div></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"10 ","pages":"Article 100264"},"PeriodicalIF":4.7,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143174020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IL-12 family cytokines and autoimmune diseases: A potential therapeutic target? IL-12家族细胞因子与自身免疫性疾病:一个潜在的治疗靶点?
IF 4.7 Q2 IMMUNOLOGY Pub Date : 2024-12-06 DOI: 10.1016/j.jtauto.2024.100263
Xiaoyu Cui , Wu Liu , Hanxue Jiang , Qihan Zhao , Yuehong Hu , Xinyue Tang , Xianli Liu , Haoran Dai , Hongliang Rui , Baoli Liu
In recent years, the discovery of IL-12 family cytokines, which includes IL-12, IL-23, IL-27, IL-35, and IL-39, whose biological functions directly or indirectly affect various autoimmune diseases. In autoimmune diseases, IL-12 family cytokines are aberrantly expressed to varying degrees. These cytokines utilize shared subunits to influence T-cell activation and differentiation, thereby regulating the balance of T-cell subsets, which profoundly impacts the onset and progression of autoimmune diseases. In such conditions, IL-12 family members are aberrantly expressed to varying degrees. By exploring their immunomodulatory functions, researchers have identified varying therapeutic potentials for each member. This review examines the physiological functions of the major IL-12 family members and their interactions, discusses their roles in several autoimmune diseases, and summarizes the progress of clinical studies involving monoclonal antibodies targeting IL-12 and IL-23 subunits currently available for treatment.
近年来,发现了IL-12家族细胞因子,包括IL-12、IL-23、IL-27、IL-35和IL-39,其生物学功能直接或间接影响各种自身免疫性疾病。在自身免疫性疾病中,IL-12家族细胞因子有不同程度的异常表达。这些细胞因子利用共享的亚基来影响t细胞的活化和分化,从而调节t细胞亚群的平衡,从而深刻影响自身免疫性疾病的发生和进展。在这种情况下,IL-12家族成员不同程度地异常表达。通过探索它们的免疫调节功能,研究人员已经确定了每个成员不同的治疗潜力。本文综述了IL-12家族主要成员的生理功能及其相互作用,讨论了它们在几种自身免疫性疾病中的作用,并总结了目前用于治疗IL-12和IL-23亚基的单克隆抗体的临床研究进展。
{"title":"IL-12 family cytokines and autoimmune diseases: A potential therapeutic target?","authors":"Xiaoyu Cui ,&nbsp;Wu Liu ,&nbsp;Hanxue Jiang ,&nbsp;Qihan Zhao ,&nbsp;Yuehong Hu ,&nbsp;Xinyue Tang ,&nbsp;Xianli Liu ,&nbsp;Haoran Dai ,&nbsp;Hongliang Rui ,&nbsp;Baoli Liu","doi":"10.1016/j.jtauto.2024.100263","DOIUrl":"10.1016/j.jtauto.2024.100263","url":null,"abstract":"<div><div>In recent years, the discovery of IL-12 family cytokines, which includes IL-12, IL-23, IL-27, IL-35, and IL-39, whose biological functions directly or indirectly affect various autoimmune diseases. In autoimmune diseases, IL-12 family cytokines are aberrantly expressed to varying degrees. These cytokines utilize shared subunits to influence T-cell activation and differentiation, thereby regulating the balance of T-cell subsets, which profoundly impacts the onset and progression of autoimmune diseases. In such conditions, IL-12 family members are aberrantly expressed to varying degrees. By exploring their immunomodulatory functions, researchers have identified varying therapeutic potentials for each member. This review examines the physiological functions of the major IL-12 family members and their interactions, discusses their roles in several autoimmune diseases, and summarizes the progress of clinical studies involving monoclonal antibodies targeting IL-12 and IL-23 subunits currently available for treatment.</div></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"10 ","pages":"Article 100263"},"PeriodicalIF":4.7,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a standardized monoclonal antibody to the inner lipoyl domain of PDC-E2 as a potential international AMA reference 开发 PDC-E2 内脂酰结构域的标准化单克隆抗体,作为潜在的国际 AMA 参照物
IF 4.7 Q2 IMMUNOLOGY Pub Date : 2024-11-23 DOI: 10.1016/j.jtauto.2024.100262
Zhuye Qin , Fangming Cheng , Mingming Zhang , Ruonan Qian , Hong Chen , Yaqin Zhao , Youtao Zhang , Yaping Dai , Chaochao Tang , Peng Jiang , Xiaoli Hua , Shen Li , Bing Zheng , Pin Yu , Xingjuan Shi , Suraj Timilsina , M. Eric Gershwin , Xiangdong Liu , Chungen Qian , Fang Qiu
The detection of antimitochondrial antibodies (AMA) is the specific diagnostic marker for primary biliary cholangitis. Indeed, it is the most specific autoantibody in clinical autoimmunity, with a high titer directed response to the inner lipoyl domain of PDC-E2. The current international reference for AMA detection is based upon sera samples of PBC patients. In rheumatic diseases, i.e. rheumatoid arthritis, great efforts are placed at development of international standards. In this study, we report the development of a monoclonal chimeric IgG1 antibody as a reference for AMA testing. A monoclonal 4G6 antibody was constructed from a murine monoclonal antibody specific for the inner lipoyl domain (ILD) of PDC-E2, by combining the variable region with the constant region of human IgG1. The 4G6 antibody recognizes all AMA epitopes containing the ILD of PDC-E2, including the classical BPO recombinant antigen in all currently available diagnostic methods. The binding affinity of the 4G6 antibody to PDC-E2 and BPO antigen reaches KD value of 7.22 × 10−11 M and 4.55 × 10−11 M, which is sufficient to use as a quantitative reference for all AMA tests. The unlimited availability of the 4G6 antibody makes it a promising candidate for use as an AMA reference or assay calibrator for the international community.
抗线粒体抗体(AMA)的检测是原发性胆汁性胆管炎的特异性诊断指标。事实上,它是临床自身免疫中最具特异性的自身抗体,对 PDC-E2 的内脂酰结构域具有高滴度的定向反应。目前国际上检测 AMA 的参考依据是 PBC 患者的血清样本。在风湿性疾病(即类风湿性关节炎)方面,人们正努力制定国际标准。在本研究中,我们报告了一种单克隆嵌合 IgG1 抗体作为 AMA 检测参考的开发情况。通过将鼠单克隆抗体的可变区与人 IgG1 的恒定区结合,构建了一种特异于 PDC-E2 内脂酰结构域(ILD)的单克隆 4G6 抗体。4G6 抗体可识别含有 PDC-E2 内脂酰结构域的所有 AMA 表位,包括目前所有可用诊断方法中的经典 BPO 重组抗原。4G6 抗体与 PDC-E2 和 BPO 抗原的结合亲和力 KD 值分别为 7.22 × 10-11 M 和 4.55 × 10-11 M,足以作为所有 AMA 检测的定量参考。4G6 抗体的无限可得性使其有希望成为国际社会的 AMA 参照物或检测校准物。
{"title":"Development of a standardized monoclonal antibody to the inner lipoyl domain of PDC-E2 as a potential international AMA reference","authors":"Zhuye Qin ,&nbsp;Fangming Cheng ,&nbsp;Mingming Zhang ,&nbsp;Ruonan Qian ,&nbsp;Hong Chen ,&nbsp;Yaqin Zhao ,&nbsp;Youtao Zhang ,&nbsp;Yaping Dai ,&nbsp;Chaochao Tang ,&nbsp;Peng Jiang ,&nbsp;Xiaoli Hua ,&nbsp;Shen Li ,&nbsp;Bing Zheng ,&nbsp;Pin Yu ,&nbsp;Xingjuan Shi ,&nbsp;Suraj Timilsina ,&nbsp;M. Eric Gershwin ,&nbsp;Xiangdong Liu ,&nbsp;Chungen Qian ,&nbsp;Fang Qiu","doi":"10.1016/j.jtauto.2024.100262","DOIUrl":"10.1016/j.jtauto.2024.100262","url":null,"abstract":"<div><div>The detection of antimitochondrial antibodies (AMA) is the specific diagnostic marker for primary biliary cholangitis. Indeed, it is the most specific autoantibody in clinical autoimmunity, with a high titer directed response to the inner lipoyl domain of PDC-E2. The current international reference for AMA detection is based upon sera samples of PBC patients. In rheumatic diseases, i.e. rheumatoid arthritis, great efforts are placed at development of international standards. In this study, we report the development of a monoclonal chimeric IgG1 antibody as a reference for AMA testing. A monoclonal 4G6 antibody was constructed from a murine monoclonal antibody specific for the inner lipoyl domain (ILD) of PDC-E2, by combining the variable region with the constant region of human IgG1. The 4G6 antibody recognizes all AMA epitopes containing the ILD of PDC-E2, including the classical BPO recombinant antigen in all currently available diagnostic methods. The binding affinity of the 4G6 antibody to PDC-E2 and BPO antigen reaches <em>K</em><sub>D</sub> value of 7.22 × 10<sup>−11</sup> M and 4.55 × 10<sup>−11</sup> M, which is sufficient to use as a quantitative reference for all AMA tests. The unlimited availability of the 4G6 antibody makes it a promising candidate for use as an AMA reference or assay calibrator for the international community.</div></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"9 ","pages":"Article 100262"},"PeriodicalIF":4.7,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142698963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of β1 adrenergic receptor autoantibodies for microvascular obstruction in patients with STEMI with Post-PCI: A prospective cohort study PCI术后STEMI患者微血管阻塞的β1肾上腺素能受体自身抗体的预后价值:一项前瞻性队列研究
IF 4.7 Q2 IMMUNOLOGY Pub Date : 2024-11-14 DOI: 10.1016/j.jtauto.2024.100261
Ning Cao , Wenxi Dang , Yanguo Xin , Jiayu Li , Shaohua Guo , Qitian Li , Hui Chen , Shun Li

Backgrounds

Coronary microvascular obstruction (MVO) frequently occurs in patients with ST-segment elevation myocardial infarction (STEMI) following percutaneous coronary intervention (PCI), leading to poor prognosis. β1 adrenergic receptor autoantibodies (β1-AA) are present in various cardiovascular diseases and correlate with cardiac damage and dysfunction. However, whether β1-AA is associated with the occurrence of MVO in patients with STEMI after PCI remains unclear.

Aims

To investigate the prognostic relationship between β1-AA and the occurrence of MVO in patients with STEMI with post-PCI.

Methods

This prospective study included 403 patients with STEMI who underwent primary PCI. The patients were divided into MVO+ and MVO- groups. Serum β1-AA levels were measured prior to primary PCI. The primary outcome was MVO, assessed through cardiac magnetic resonance imaging at 5–7 days after PCI.

Results

A total of 127 MVO+ and 276 MVO– patients were identified. Patients with MVO + exhibited higher β1-AA optical density (OD) compared to MVO- patients. β1-AA OD, pNT-proBNP, pCK-MB and pTNI were positively associated with MVO following PCI. Notably, the assocition between β1-AA levels and MVO risk strengthened with increasing pNT-proBNP levels. The combination of β1-AA, pNT-proBNP and pTNI yielded the most efficient MVO prediction with an area under the ROC curve of 0.87 (95 % CI: 0.83–0.90).

Conclusions

β1-AA is significantly associated with the occurrence of MVO in STEMI patients following primary PCI. The combination of β1-AA with pNT-proBNP and pTNI improves predictive accuracy, providing a more robust and effective strategy for assessing MVO risk.
背景经皮冠状动脉介入治疗(PCI)后,ST 段抬高型心肌梗死(STEMI)患者经常会出现冠状动脉微血管阻塞(MVO),导致预后不良。β1肾上腺素能受体自身抗体(β1-AA)存在于各种心血管疾病中,并与心脏损伤和功能障碍相关。目的研究 STEMI 患者接受 PCI 后,β1-AA 与 MVO 发生之间的预后关系。方法这项前瞻性研究纳入了 403 名接受初级 PCI 的 STEMI 患者。将患者分为 MVO+ 组和 MVO- 组。在初级 PCI 之前测量血清 β1-AA 水平。主要结果是通过 PCI 后 5-7 天的心脏磁共振成像评估 MVO。与 MVO- 患者相比,MVO + 患者表现出更高的β1-AA 光密度(OD)。β1-AA OD、pNT-proBNP、pCK-MB 和 pTNI 与 PCI 后的 MVO 呈正相关。值得注意的是,β1-AA 水平与 MVO 风险之间的关联随着 pNT-proBNP 水平的增加而加强。β1-AA、pNT-proBNP 和 pTNI 的组合能最有效地预测 MVO,其 ROC 曲线下面积为 0.87(95 % CI:0.83-0.90)。β1-AA与pNT-proBNP和pTNI的结合提高了预测的准确性,为评估MVO风险提供了一种更稳健、更有效的策略。
{"title":"Prognostic value of β1 adrenergic receptor autoantibodies for microvascular obstruction in patients with STEMI with Post-PCI: A prospective cohort study","authors":"Ning Cao ,&nbsp;Wenxi Dang ,&nbsp;Yanguo Xin ,&nbsp;Jiayu Li ,&nbsp;Shaohua Guo ,&nbsp;Qitian Li ,&nbsp;Hui Chen ,&nbsp;Shun Li","doi":"10.1016/j.jtauto.2024.100261","DOIUrl":"10.1016/j.jtauto.2024.100261","url":null,"abstract":"<div><h3>Backgrounds</h3><div>Coronary microvascular obstruction (MVO) frequently occurs in patients with ST-segment elevation myocardial infarction (STEMI) following percutaneous coronary intervention (PCI), leading to poor prognosis. β<sub>1</sub> adrenergic receptor autoantibodies (β<sub>1</sub>-AA) are present in various cardiovascular diseases and correlate with cardiac damage and dysfunction. However, whether β<sub>1</sub>-AA is associated with the occurrence of MVO in patients with STEMI after PCI remains unclear.</div></div><div><h3>Aims</h3><div>To investigate the prognostic relationship between β<sub>1</sub>-AA and the occurrence of MVO in patients with STEMI with post-PCI.</div></div><div><h3>Methods</h3><div>This prospective study included 403 patients with STEMI who underwent primary PCI. The patients were divided into MVO+ and MVO- groups. Serum β<sub>1</sub>-AA levels were measured prior to primary PCI. The primary outcome was MVO, assessed through cardiac magnetic resonance imaging at 5–7 days after PCI.</div></div><div><h3>Results</h3><div>A total of 127 MVO+ and 276 MVO– patients were identified. Patients with MVO + exhibited higher β<sub>1</sub>-AA optical density (OD) compared to MVO- patients. β<sub>1</sub>-AA OD, pNT-proBNP, pCK-MB and pTNI were positively associated with MVO following PCI. Notably, the assocition between β<sub>1</sub>-AA levels and MVO risk strengthened with increasing pNT-proBNP levels. The combination of β<sub>1</sub>-AA, pNT-proBNP and pTNI yielded the most efficient MVO prediction with an area under the ROC curve of 0.87 (95 % CI: 0.83–0.90).</div></div><div><h3>Conclusions</h3><div>β<sub>1</sub>-AA is significantly associated with the occurrence of MVO in STEMI patients following primary PCI. The combination of β<sub>1</sub>-AA with pNT-proBNP and pTNI improves predictive accuracy, providing a more robust and effective strategy for assessing MVO risk.</div></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"9 ","pages":"Article 100261"},"PeriodicalIF":4.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dissecting the genetic basis and mechanisms underlying the associations between multiple extrahepatic factors and autoimmune liver diseases 剖析多种肝外因子与自身免疫性肝病相关的遗传基础和机制。
IF 4.7 Q2 IMMUNOLOGY Pub Date : 2024-11-05 DOI: 10.1016/j.jtauto.2024.100260
Zheng Zhang , Jiayi Zhang , Xinyang Yan , Jiachen Wang , Haoxiang Huang , Menghao Teng , Qingguang Liu , Shaoshan Han

Background

Autoimmune liver diseases (AILDs) encompass autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). The onset of these diseases is fundamentally influenced by genetic susceptibility. Although various extrahepatic factors are potentially linked to AILDs, the genetic underpinnings and mechanisms of these associations remain unclear.

Methods

Utilizing large-scale genome-wide association study (GWAS) data, this study systematically investigated the relationships between extrahepatic autoimmune diseases (EHAIDs), immune cells, and various triggering factors with AILDs. Mendelian randomization (MR) was employed to assess the causal effects of these extrahepatic factors on AILDs, complemented by linkage disequilibrium score (LDSC) regression to uncover shared genetic architecture and causal effects underlying the associations between autoimmune diseases. We employed colocalization, enrichment analysis, and protein-protein interaction (PPI) network to identify the functions of shared loci. Additionally, we proposed that activated immune cells in the circulation may contribute to liver and biliary tract inflammation via migration, mediating the impact of extrahepatic factors on AILDs. This hypothesis was tested using two mediation analysis methods: two-step MR (TSMR) and multivariable MR (MVMR).

Results

Causal associations between multiple extrahepatic factors and AILDs were identified. Notably, CD27+ B cells were found to be a risk factor for PBC, while PSC progression was associated with CD28+ CD8+ T cells exhaustion and increased levels of CD28 CD8+ T cells. Mediation analyses revealed 64 pathways via TSMR and 15 pathways via MVMR, indicating that the effects of extrahepatic factors on AILDs may be mediated by circulating immune cells. The shared genetic architecture also contributed to these associations. Analysis of shared loci and gene functions identified ATXN2 as being shared between PBC and 9 EHAIDs, while SH2B3 and PSMG1 were shared with 6 and 5 EHAIDs, respectively, in PSC.

Conclusions

Our research compared three distinct AILDs, enhancing the understanding of their etiology and providing new evidence on risk factors, diagnostic markers, and potential therapeutic targets.
背景:自身免疫性肝病(AILDs)包括自身免疫性肝炎(AIH)、原发性胆道炎(PBC)和原发性硬化性胆管炎(PSC)。这些疾病的发病基本上受遗传易感性的影响。尽管各种肝外因素可能与aild有关,但这些关联的遗传基础和机制尚不清楚。方法:利用大规模全基因组关联研究(GWAS)数据,系统研究肝外自身免疫性疾病(EHAIDs)、免疫细胞和各种触发因素与该病的关系。采用孟德尔随机化(MR)来评估这些肝外因素对aild的因果影响,并辅以连锁不平衡评分(LDSC)回归来揭示自身免疫性疾病之间关联的共同遗传结构和因果影响。我们采用共定位、富集分析和蛋白-蛋白相互作用(PPI)网络来确定共享位点的功能。此外,我们提出循环中活化的免疫细胞可能通过迁移导致肝脏和胆道炎症,介导肝外因子对AILDs的影响。采用两步MR (TSMR)和多变量MR (MVMR)两种中介分析方法对这一假设进行了检验。结果:确定了多种肝外因素与AILDs之间的因果关系。值得注意的是,CD27+ B细胞被发现是PBC的一个危险因素,而PSC的进展与CD28+ CD8+ T细胞衰竭和CD28- CD8+ T细胞水平升高有关。介导分析揭示了64条TSMR通路和15条MVMR通路,表明肝外因子对AILDs的影响可能是通过循环免疫细胞介导的。共同的遗传结构也促成了这些关联。共享位点和基因功能分析发现,PBC与9个EHAIDs共享ATXN2, PSC中分别与6个和5个EHAIDs共享SH2B3和PSMG1。结论:我们的研究比较了三种不同的aild,增强了对其病因的理解,并为危险因素、诊断标志物和潜在治疗靶点提供了新的证据。
{"title":"Dissecting the genetic basis and mechanisms underlying the associations between multiple extrahepatic factors and autoimmune liver diseases","authors":"Zheng Zhang ,&nbsp;Jiayi Zhang ,&nbsp;Xinyang Yan ,&nbsp;Jiachen Wang ,&nbsp;Haoxiang Huang ,&nbsp;Menghao Teng ,&nbsp;Qingguang Liu ,&nbsp;Shaoshan Han","doi":"10.1016/j.jtauto.2024.100260","DOIUrl":"10.1016/j.jtauto.2024.100260","url":null,"abstract":"<div><h3>Background</h3><div>Autoimmune liver diseases (AILDs) encompass autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). The onset of these diseases is fundamentally influenced by genetic susceptibility. Although various extrahepatic factors are potentially linked to AILDs, the genetic underpinnings and mechanisms of these associations remain unclear.</div></div><div><h3>Methods</h3><div>Utilizing large-scale genome-wide association study (GWAS) data, this study systematically investigated the relationships between extrahepatic autoimmune diseases (EHAIDs), immune cells, and various triggering factors with AILDs. Mendelian randomization (MR) was employed to assess the causal effects of these extrahepatic factors on AILDs, complemented by linkage disequilibrium score (LDSC) regression to uncover shared genetic architecture and causal effects underlying the associations between autoimmune diseases. We employed colocalization, enrichment analysis, and protein-protein interaction (PPI) network to identify the functions of shared loci. Additionally, we proposed that activated immune cells in the circulation may contribute to liver and biliary tract inflammation via migration, mediating the impact of extrahepatic factors on AILDs. This hypothesis was tested using two mediation analysis methods: two-step MR (TSMR) and multivariable MR (MVMR).</div></div><div><h3>Results</h3><div>Causal associations between multiple extrahepatic factors and AILDs were identified. Notably, CD27<sup>+</sup> B cells were found to be a risk factor for PBC, while PSC progression was associated with CD28<sup>+</sup> CD8<sup>+</sup> T cells exhaustion and increased levels of CD28<sup>−</sup> CD8<sup>+</sup> T cells. Mediation analyses revealed 64 pathways via TSMR and 15 pathways via MVMR, indicating that the effects of extrahepatic factors on AILDs may be mediated by circulating immune cells. The shared genetic architecture also contributed to these associations. Analysis of shared loci and gene functions identified ATXN2 as being shared between PBC and 9 EHAIDs, while SH2B3 and PSMG1 were shared with 6 and 5 EHAIDs, respectively, in PSC.</div></div><div><h3>Conclusions</h3><div>Our research compared three distinct AILDs, enhancing the understanding of their etiology and providing new evidence on risk factors, diagnostic markers, and potential therapeutic targets.</div></div>","PeriodicalId":36425,"journal":{"name":"Journal of Translational Autoimmunity","volume":"10 ","pages":"Article 100260"},"PeriodicalIF":4.7,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Translational Autoimmunity
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1